ProMIS Neurosciences Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

PMN$4.05-2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 25, 2026.


	PROMIS NEUROSCIENCES INC.

	By:	/s/ Neil Warma
		Neil Warma
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 25, 2026 by the following persons on behalf of the registrant and in the capacities indicated:



Signature		Title

/s/ Neil Warma		Chief Executive Officer and Director
Neil Warma		(Principal Executive Officer)

/s/ Daniel Geffken		Chief Financial Officer
Daniel Geffken		(Principal Financial Officer)

/s/ Max Milbury		Vice President, Finance
Max Milbury		(Principal Accounting Officer)

/s/ Eugene Williams		Director
Eugene Williams

/s/ Neil Cashman		Chief Science Officer and Director
Neil Cashman

/s/ Patrick Kirwin		Director
Patrick Kirwin

/s/ Joshua Mandel-Brehm		Director
Joshua Mandel-Brehm

/s/ Maggie Shafmaster		Director
Maggie Shafmaster

/s/ William Wyman		Director
William Wyman
/s/ Slanix Paul Alex		Director
Slanix Paul Alex

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.